B. Riley lowered the firm’s price target on Aspen Aerogels (ASPN) to $10 from $22 and keeps a Buy rating on the shares following the Q1 report. The firm cut estimates, noting Aspen guided below expectations. The company is educing fixed costs, with a line of sight to meaningful growth in 2027, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASPN:
- Aspen Aerogels price target lowered to $8 from $16 at Roth Capital
- Aspen Aerogels Faces Challenges Amid New Contract Win
- Aspen Aerogels Navigates Challenges in Earnings Call
- Aspen Aerogels downgraded to Perform at Oppenheimer on deteriorating demand
- Aspen Aerogels downgraded to Perform from Outperform at Oppenheimer